Is the life sciences industry a good bet right now? BioSpace put a poll in the field, which elicited mixed results. In order to get a clearer picture, BioSpace spoke to a few knowledgeable industry experts.  

Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.

Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.

Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.

Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.

According to PitchBook’s 2021 U.S. Venture Capital Outlook report, biotech and pharma VC deal activity will probably exceed $20 billion during 2021.

Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.

RA Capital Management closed the venture capital firm’s second venture fund at $461 million, aimed at a continued investment strategy into privately held life sciences companies.

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.  

Geeta Vemuri is a trailblazer. Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.